Volume | 519,755 |
|
|||||
News | - | ||||||
Day High | 1.71 | Low High |
|||||
Day Low | 1.585 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Adicet Bio Inc | ACET | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.62 | 1.585 | 1.71 | 1.61 | 1.62 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,215 | 519,755 | $ 1.61 | $ 839,053 | - | 1.10 - 6.65 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:14:16 | formt | 159 | $ 1.63 | USD |
Adicet Bio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
98.42M | 43.16M | - | 0 | -142.66M | -3.31 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Adicet Bio News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACET Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.49 | 1.71 | 1.33 | 1.46 | 1,285,997 | 0.14 | 9.40% |
1 Month | 2.14 | 2.25 | 1.33 | 1.56 | 1,822,874 | -0.51 | -23.83% |
3 Months | 2.42 | 2.54 | 1.33 | 1.93 | 1,371,882 | -0.79 | -32.64% |
6 Months | 1.19 | 3.77 | 1.10 | 2.32 | 1,365,125 | 0.44 | 36.97% |
1 Year | 6.40 | 6.65 | 1.10 | 2.42 | 1,014,245 | -4.77 | -74.53% |
3 Years | 15.05 | 21.87 | 1.10 | 7.75 | 694,073 | -13.42 | -89.17% |
5 Years | 14.98 | 21.87 | 1.10 | 7.99 | 588,613 | -13.35 | -89.12% |
Adicet Bio Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. |